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ABSTRACT 
 
 
 
Equations that estimate GFR (eGFR) are widely used in clinical practice to 
estimate kidney function in sub-Saharan Africa, but have not been validated for 
use in this region. This study assessed the performance of eGFR equations in 
adults evaluated for suitability for live kidney donation against a gold standard 
radionuclear GFR measurement (mGFR) and determined their usefulness for 
screening live kidney donors in South Africa. 
 
This study was a retrospective record review of 350 adults evaluated for living 
kidney donation from 1996 – 2013 at Charlotte Maxeke Johannesburg 
Academic Hospital (CMJAH) and Wits Donald Gordon Medical Centre 
(WDGMC). Their eGFR was calculated using CG, 4-v MDRD and CKD-EPI 
equations. Plasma clearance of 51Cr-EDTA was used as a reference method for 
mGFR. 
 
The  4-v  MDRD  (with  and  without  ethnicity  adjustment)  and  the  CKD-EPI 
(without ethnicity adjustment) equations underestimated the mGFR (negative 
bias of -8 mL/min/1.73m2, -16 mL/min/-1.73m2 and -6.4 mL/min/1.73m2 
respectively).However, the bias associated with the average mGFR using the 
CG and CKD-EPI (with ethnicity adjustment) equations was not significant (2.3 
mL/min/1.73m2 and 0.6 respectively).Use of the ethnicity factor resulted in 
overestimation of mGFR for both the 4v-MDRD equation (by 24.2ml/min/1.73m2 
compared  to  6.8  ml/min/1.73m2   without  it)  and  the  CKD-EPI  equation  (by 
21.8ml/min/1.73m2, compared to 7.6ml/min/1.73m2, without the ethnicity factor). 
 
In conclusion, this study showed that almost half of adults screened for living 
donation in Johannesburg were not eligible due to comorbid hypertension, 
diabetes and unexplained kidney disease. In addition, the error statistics 
worsened as mGFR increased and all four prediction equations had a low 
sensitivity for determining individuals with a GFR <80 ml/min/1.73m2. Based on 
the findings in this study, use of a gold standard measured GFR should be the 
preferred method for assessing kidney function in potential living kidney donors 
in South Africa. 
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Assessment of GFR in the evaluation of potential living kidney donors at the 
 
Wits   Donald   Gordon   Medical   Center   (WDGMC)   and   Charlotte   Maxeke 
 
Johannesburg Academic Hospital (CMJAH) 
 
 
 
 
1. Introduction 
 
Chronic kidney disease (CKD) is now a major public health problem affecting an 
estimated 500 million people globally - that is approximately 1 in 10 adults (1, 2). 
There is little information on the burden of CKD in sub Saharan Africa and the 
mortality associated with advanced stages is high, as few people with end stage 
kidney disease (ESKD) can access adequate medical care (3). In countries such as 
South Africa where the prevalence of common risk factors such as diabetes, 
hypertension and HIV is high, the risk of CKD is thought to be similarly high, though 
there is little local data to substantiate or refute this (4). While chronic dialysis is a 
therapeutic option, the optimal treatment for ESKD is kidney transplantation. Potential 
kidney donors may be deceased or living and if living, related or unrelated to the 
recipient. 
 
Living donor kidney transplants have a better outcome than deceased donor with 
regard to recipient and graft survival (5). In Africa, It has been reported that kidney 
transplantation is only done in South Africa, Nigeria, Tunisia and Egypt. The source of 
most of these transplants arise from l iving donors except in South Africa where 60 
- 80% are deceased donors (4). Even in South Africa, which is regarded as a 
relatively wealthy country in Africa, many patients with ESKD fail to access dialysis 
and transplantation, particularly in the public health care sector (4). Scarce 
resources, shortage of donors as well as spiritual and cultural beliefs have all been 
said to contribute to limiting access to kidney transplantation (4, 6). 
 
Worldwide there is an increasing trend towards the use of living donors, both related 
and unrelated (7). However, the transplant community in South Africa is still heavily 
reliant on deceased donors. According to the organ donor foundation statistics there 
were 231 kidney transplants in South Africa in the year 2015 and 40% were living 
donors (8). One of the factors that may contribute to lower than preferred living 
donation is the unsuitability of screened donors. 
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In one previous South African study, 59.7% of potential living donors were not suitable 
to donate for various reasons. Medical reasons for non-donation included: presence 
of p e r s i s t e n t  n o n -orthostatic proteinuria, glomerular filtration rate (GFR) below 
80mL/min/1.73m2, abnormalities of the urinary tract, uncontrolled hypertension, obesity, 
vasculopathy and heart disease, diabetes mellitus, infections (HIV, chronic hepatitis B 
and C), psychological problems, liver disease and malignancies (7). Similar findings 
have been documented elsewhere, such as in Italy where 56.9% of potential donors 
were unsuitable (9). 
 
Kidney transplant is now established to be a safe procedure and perioperative deaths 
are extremely rare (4, 10). However, following unilateral nephrectomy donors are 
classified as having CKD due to an observed decrease in the GFR (10). In one study, 
both the lifespan and quality of life of carefully selected donors was found to be similar 
to that of the general population (11). However, a more recent study found that living 
kidney donors had a small absolute increase in the risk of developing ESKD over a 
median of 7.6 years compared to matched healthy non-donors (12). Of primary 
importance therefore in the screening process is an estimation of renal function to 
ensure that donors are not unduly compromised. Therefore, one of the most critical 
components in the evaluation of the living donor is the method used for assessing 
kidney function, usually measured by determining the glomerular filtration rate (GFR). 
 
The GFR is the sum of filtration rates of all functioning nephrons and thus a measure 
of kidney function that’s currently accepted as the best available measure of 
functioning renal mass (13).  It is critical to accurately assess GFR in potential living 
kidney donors to ensure that the donor has sufficient functional reserve to donate one 
kidney without compromising their health, while the recipient receives an adequately 
functioning kidney. Although the GFR can be measured with precision using specific 
filtration markers such as inulin, 125 I-iothalamate, chromium 51 ethylene diamine 
tetra acetic acid (51Cr EDTA), technetium-99m-diethylene triamine pentaacetic acid 
(Tc-99m DTPA) and iohexol, these methods are not readily available for regular clinical 
use. Furthermore, they are not only expensive and time consuming but also require 
special skills and equipment. Nevertheless, the current gold standard for direct GFR 
measurement is by the use of radioisotopes (51Cr EDTA, Tc-99m DTPA), and iohexol 
(13, 14). 
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Renal function may also be evaluated by the use of radiologic investigations and 
surrogate markers. CT scanning measures functional renal volume while MRI 
measures renal anatomy, function and vascular morphology. Radiologic methods are 
similarly expensive, complex and not readily available. As an alternative, using serum 
creatinine as a surrogate marker for GFR, equations have been derived to estimate 
GFR (eGFR) including: the MDRD (modification of diet in renal disease), CKD-EPI 
(chronic kidney disease-epidemiology collaboration) and Cockroft-Gault equations, 
and 24 hour urine creatinine clearance (15, 16). 
 
These equations have been developed in Caucasians and African Americans but are 
widely applied to other populations in clinical practice to estimate kidney function, 
including in sub Saharan Africa (17). Adjustments for ethnicity that were derived from 
African American studies, although widely applied to Africans, has not been validated. 
In fact, isolated studies have demonstrated that these adjustments for ethnicity worsen 
performance of the equations in SSA (14). 
 
The Cockroft-Gault equation was derived in 1976, in Canada, using an unstandardized 
creatinine assay with a predominantly white male sample. The equation adjusts for 
weight and gender. The inclusion of the weight factor is intended to adjust for muscle 
mass, a determinant of serum creatinine concentration. Its performance is adversely 
affected in clinical situations where change in weight is not due to a change in muscle 
mass e.g. oedematous states and obesity. In different studies the CG has been shown 
to overestimate GFR by 16 to 23% (18). 
 
The MDRD study equation was developed in the USA using data from a sample of 
adult patients with CKD (GFR below 60mL/min/1.73m2), the majority of whom were 
Caucasian with far fewer African American participants. The 4-variable adaptation of 
the MDRD equation has been widely used in clinical practice since 1999 (19). It 
provides an estimate of GFR using serum creatinine, age, sex and an adjustment for 
African American ethnicity, normalized to 1.73 meter squared body surface area 
(BSA), the accepted average adult surface area (20). The equation should only be 
used when the renal function is stable and is not recommended for use in individuals 
with abnormal basal creatinine production caused by extreme body size/muscle 
mass, obesity, severe malnutrition, amputees, paraplegics or vegetarians and those 
on creatine supplements (16). In a study on black South African patients with CKD 
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at Chris Hani Baragwanath Academic Hospital (CHBAH) in Soweto, Johannesburg, 
the 4-variable MDRD eGFR overestimated GFR with a positive bias of 27% using the 
adjustment factor for African Americans, while the bias was reduced to 5% without this 
(14). 
 
Because the accuracy of the 4-variable MDRD equation was poor at higher eGFR, the 
CKD-EPI equation was developed in 2009. The data to derive the equation were 
sourced from 8,254 individuals from 10 studies, including the MDRD study, and 
validated in an additional 16 studies containing 3,896 individuals. The variables used 
were the same as those for MDRD equation i.e. serum creatinine level, age, race and 
sex. The CKD-EPI demonstrated higher GFR levels for African Americans compared 
to whites at all serum creatinine levels. To accommodate this, an African American 
adjustment factor of 1.159 was derived, which is different from the one used in the 4- 
variable MDRD equation. The performance of the CKD-EPI equation is superior to the 
4-variable MDRD equation at eGFR between 60 and 120 mL/min/1.73m2, while the 
results are as accurate below 60 mL/min/1.73m2 (21, 22). Again, when the 
adjustment factor for African ethnicity was applied to black South African patients at 
CHBAH, all levels of GFR were found to be overestimated but more so, for those with 
values below 60 mL/min/1.73m2.  Less bias was noted when the adjustment factor 
for African Americans was excluded (14). 
 
 
Creatinine clearance over 24 hours, calculated as a rate (CCr) is an alternative method 
for estimating GFR. This is estimated from measuring the creatinine excreted in a 24 
hour urine specimen and a serum creatinine specimen obtained during the same 
period (14). Fifteen percent of creatinine is actively secreted in the proximal tubule of 
the kidney and less in the small bowel. Both anatomical regions manifest 
proportionately increased secretion with worsening kidney function.  As a result, the 
CCr overestimates glomerular filtration by about 10-40% compared to actual GFR (16). 
In addition, collecting urine over a 24 hour period is inconvenient to most people and 
therefore unlikely to be carried out with accuracy (14). For these reasons, this test is 
not routinely used. In a study on African Americans with hypertensive nephrosclerosis, 
CCr was found to weakly correlate with actual GFR (23). 
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All the eGFR equations have not been evaluated in Africans. In the transplant setting, 
there are no studies assessing the performance of eGFR in healthy donors. This is 
particularly relevant in South Africa because access to gold standard or measured 
GFR (mGFR) is limited and the cost is high, so using eGFR is cheaper, but must be 
scientifically justifiable. Similarly, if mGFR is recommended this needs to be 
substantiated by local data. Currently there are no such studies that have been 
published from South Africa. Guidelines for clinicians are unclear from the transplant 
community, and all recommendations are derived from the northern hemisphere. The 
2015 clinical practice guidelines for the evaluation and follow up of live kidney donors 
from KDIGO recommends using eGFR derived from the 2009 CKE-EPI creatinine 
equation in North America, Europe and Australia. In other regions, studies are 
recommended to address prediction accuracy among racial and ethnic groups for 
whom the accuracy of eGFR is less certain (24). 
 
 
 
2. Aim 
 
This aim of this study was to investigate the eligibility of potential living kidney donors 
in the Johannesburg region who presented for investigation, to compare the 
performance of estimated GFR equations to a gold standard reference method for 
evaluating their kidney function and, in those who donated a kidney, to determine the 
one year recipient and graft survival after transplant. 
 
 
3. Objectives 
 
1. To describe the demographics and success rates for donation for potential living 
kidney donors assessed at the WDGMC and CMJAH between 1996 and 2013. 
2. To determine the one year patient and graft survival in the living donor kidney 
transplant recipients who received a kidney from the living donors in the study sample 
 
3. To calculate the eGFR for each potential living kidney donor using the CG, 4v-
MDRD, 4v-MDRD-e, CKD-EPI, and CKD-EPI-e equations; as well as urinary CCr 
 
4. To compare the performance of the urinary CCr, CG, 4v-MDRD, 4v-MDRD-e, CKD-
EPI and the CKD-EPI-e equations to the gold standard (51Cr EDTA) and determine the 
effect of age, weight, race and gender on their performance 
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5. To compare the performance of all estimating equations in relation to the measured 
GFR of 80ml/min/m2-which is the mGFR level below which donors are considered 
ineligible for kidney donation 
 
4. Methods 
 
A retrospective record review of 350 adults evaluated for living kidney donation from 
 
1996 – 2013 at Charlotte Maxeke Johannesburg Academic Hospital (CMJAH) and 
Wits Donald Gordon Medical Centre (WDGMC) was performed. Both hospitals are 
specialist referral sites for kidney transplantation and comprise part of the Faculty of 
Health Sciences Academic Teaching Hospital Complex, University of Witwatersrand, 
in Johannesburg, South Africa. Ethical clearance for this study was obtained from the 
Human Research Ethics Committee (Medical) of the University of Witwatersrand 
(M140922) (appendix A). Data were collected from numerous sources. Clinical data 
were collected from the transplant units at CMJAH and WDGMC, laboratory data were 
collected from NHLS, private laboratories, namely Lancet, Ampath, Wits Pathology 
and the radionuclear laboratory in the department of Surgery, Faculty of Health 
Sciences, and University of Witwatersrand. 
 
 
 
 
4.1 Evaluation of potential living kidney donors 
 
In transplant units in Johannesburg, potential donors undergo a detailed evaluation to 
determine their suitability. They are assessed by a senior nephrologist not involved in 
the care of potential recipients together with a psychologist and a social worker. 
Potential contraindications to donation include a history of cancer with less than 5 
years of tumor-free survival, heart disease (e.g. ischaemic heart disease, valvular 
heart disease and cardiomyopathy), type 1 and type 2 diabetes mellitus or impaired 
glucose tolerance, chronic active hepatitis B or C infection, uncontrolled hypertension 
or hypertension with evidence of target organ damage, unexplained persistent 
proteinuria and hematuria, and obesity (body mass index >35 kg/m2) (25). If none of 
these exclusions are found, routine medical work up is commenced with the 
following tests: a full blood count, urea and electrolytes, creatinine, liver function, lipid 
and coagulation profile, screening for the following infections - human 
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immunodeficiency virus (HIV), hepatitis B, C, treponema pallidum (syphilis), 
cytomegalovirus (CMV),Epstein Barr virus (EBV), ABO blood grouping and Centre 
for Disease Control (CDC) cross match, human leucocyte antigen(HLA) typing, urine 
for microscopy, culture and sensitivity, 24 hour urine protein excretion and / or urine 
protein: creatinine ratio, urine albumin creatinine ratio and a radionuclear mGFR. 
Other investigations required include: an electrocardiogram, a chest radiograph, 
abdominal ultrasound, a mammogram for women above 50 years of age and 
Papanicolau smears for sexually active women, prostate specific antigen levels for 
men over the age of 50 years. Once potential donors successfully complete the 
above, the last test required is a computed tomography angiogram to evaluate 
renovascular anatomy so that surgery can be planned (4, 26). 
 
 
4.2 Data collection for potential living kidney donors 
 
The following data were collected: age at screening (years); gender; height (cm); 
weight (kg); body mass index (BMI) (kg/m2); ethnicity (self-reported as one of the 
following: White, Black, Coloured, Asian); hospital site for investigations (CMJAH, 
CHBAH, WDGMC, other) suitability for donation: if unsuitable, reason for unsuitability. 
 
 
 
4.3 Evaluation of kidney function in potential living kidney donors 
 
For the evaluation of kidney function, plasma clearance of 51Cr-EDTA was used as the 
gold standard reference method for measured GFR (m-GFR) and normalised to BSA 
using the Du Bois equation (27). 
 
Using serum creatinine, the following estimating equations were used to calculate 
eGFR: 
 
 
 
 
1.  Re-expressed 4 -variable Modification of Diet in Renal Disease (4-vMDRD)     
equation (28): 
 
eGFR (mL/min/1.73m2) = 175 x [S-Cr (µmol/L)/88.4]-1.154 x age (years)-0.203  x 
 
(0.742 if female) x (1.1212 if African American) 
  
8 
 
2.  Cockroft-Gault (CG) equation (18) normalised to 1.73m2(29): 
 
eGFR (mL/min/1.73m2) = [140-age (years) x weight (kg) x (0.85 if female) x 
 
1.73m2)] / [S-Cr (µmol/L) x 0.814 x BSA (m2)] 
 
3.  Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation (30): 
 
eGFR (mL/min/1.73m2) = 141 × min (S-Cr /κ, 1)α × max(S-Cr /κ, 1)-1.209 × 
 
0.993Age × 1.018 [if female] × 1.159 [if black] 
 
where: 
 
S-Cr is serum creatinine in µmol/L, 
 
κ is 61.9 for females and 79.6 for males, 
 
α is -0.329 for females and -0.411 for males, 
min indicates the minimum of S-Cr /κ or 1, 
and max indicates the maximum of S-Cr /κ or 1. 
 
4.  24 hour urine creatinine clearance (24h CCr) in mL/min/1.73 m2 (14) 
 
 
 
 
4.4 Data collection for kidney transplant recipients 
 
The following data were collected: date and hospital where transplanted, cold 
ischaemic time (minutes), HLA (human leucocyte antigen) matching based on A, B 
and DR antigens; delayed graft function (defined as the need for dialysis within the first 
6 weeks post-transplant); surgical complications (graft nephrectomy, wound 
dehiscence, wound sepsis, wound hematoma or haemorrhage, sloughed ureter, urine 
leak, urinoma, ureteric obstruction, hydronephrosis, lymphocele, renal vein 
thrombosis/stenosis, renal artery thrombosis/stenosis); hospital/name of doctor where 
one year follow up was done; at 1 year after kidney transplant: recipient and graft 
survival, graft rejection (biopsy proven / or not) and serum creatinine (umol/L). 
 
 
 
4.5 Data management 
 
Study data were collected and managed using REDCap which is hosted at the 
University   of   Witwatersrand   with   assistance   of   the   research   office   at   the 
WDGMC. REDCap (Research Electronic Data Capture) is a secure, web-based 
application designed to support data capture for research studies, providing 1) an 
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intuitive interface for validated data entry; 2) audit trails for tracking data manipulation 
and export procedures; 3) automated export procedures for seamless data downloads 
to common statistical packages; and 4) procedures for importing data from external 
sources (31). It is compliant with the protection of personal information act (PoPI act), 
access is password protected, and has been made available to staff and students of 
the Faculty of Health Sciences at the University of Witwatersrand. 
 
 
 
5. Statistical analysis 
 
 
The data file was structured and cleaned in consultation with the statistician and 
uncorrected GFR values were deleted. Descriptive analysis of the data was carried out 
as follows:   Categorical variables were summarised by frequency and percentage 
tabulation, and illustrated by means of bar charts. Continuous variables were 
summarised by the mean, standard deviation, median and interquartile range, and 
their distribution illustrated by means of histograms. 
 
The relationship between the gold standard (mGFR) and each of the five estimates of 
GFR (eGFR), namely CG, *4-v MDRD and *CKD-EPI (*each with/without adjustment 
for African American ethnicity), was investigated using Bland-Altman plots. For the 
Bland-Altman analysis, mGFR was used in place of the mean of the two methods to 
be compared, since the mGFR is a gold standard. 
 
The bias was regressed against the mGFR, age, gender, ethnicity, and weight to 
determine if these factors play a role in accounting for the observed differences 
between the methods. 
 
Further statistics were derived to assess the relationship between each eGFR and 
mGFR in relation to the clinical criterion for eligibility for donation, which is mGFR >=80 
mL/min/1.73m2. Overall, and within each of the following mGFR subgroups:  <80 and 
>=80 mL/min/1.73m2 the following was determined: 
 
 
    bias: median of difference between estimated and measured GFR 
 
 
    % bias: median of percentage difference between estimated and measured 
 
GFR
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    P30: percentage of estimated GFR values within 30% of the gold standard value 
 
 
    IQR: interquartile range of difference between estimated and measured GFR 
 
 
    RMSE:  root mean square error 
 
 
The estimated GFR equations were also assessed by their sensitivity, specificity, 
positive predictive value (PPV) and negative predictive value (NPV) for the 
identification of subjects with mGFR < 80 mL/min/1.73m2. Data analysis was carried 
out using SAS. The 5% significance level was used. 
 
 
Calculation of sample size requirements was based on the key research question to 
be answered, in this case the method agreement analysis.    Bland-Altman analysis 
requires at least 60 (preferably 100) samples (32). 
 
 
 
6. Results 
 
 
All potential donors at the WDGMC and CMJAH who were evaluated for potential living 
kidney donation from 1996 to 2013 were eligible. All participants had to have a serum 
creatinine measured using an isotope dilution mass spectrometry (IDMS) traceable 
assay, a gold standard measured GFR radionuclide scan (51Cr EDTA) and /or 24 hour 
urine CCr. Those with incomplete data were excluded from the final data set. 
 
 
 
 
6.1 Eligibility of potential living kidney donors 
 
A total of 350 potential living kidney donors were reviewed, the majority of whom were 
evaluated at CMJAH (274/350; 78.3%). The demographics and anthropometry are 
depicted in table 1. The majority were obese, young women of black ethnic origin. 
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Table1.Characteristics of potential living kidney donors at CMJAH and WDGMC 
 
(1996-2013) 
 
 
 
Variable 
 
 
Category 
 
Overall 
 
n (%) 
 
Age 
 
37.0 years (sd 8.9; range 19-59 years) 
 
Weight 
 
71.5 kg (sd 13.4; range 43-116 kg) 
 
Height 
 
166.5 cm (sd 9.6; range 144-195 cm) 
 
Body mass index (BMI) 
 
26.2 kg/m2 (sd 4.0; range 16.6-36.4 kg/m2) 
 
 
 
 
Hospital 
 
CMJAH 
 
274/350 (78.3%) 
 
WDGMC 
 
68/350 (19.4%) 
 
Other referral sites 
 
8/350 (2.3%) 
 
Gender 
 
female 
 
206/350 (58.9%) 
 
Ethnicity (self-reported) 
 
black 
 
139/350 (39.7%) 
 
white 
 
115/350 (32.9%) 
 
asian/indian 
 
27/350 (7.7%) 
 
mixed race 
 
23/350 (6.6%) 
 
 
 
Of those evaluated, 52.3% were suitable for donation. The main reasons for 
unsuitability were obesity (31/166; 18.7%), hypertension (26/166; 15.7%) and 
unexplained kidney disease (22/166; 13.3%) as illustrated in table 2. 
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Variable 
 
Category 
Overall 
n (%) 
 
 
 
 
 
Kidney function 
predonation 
[median(IQR);range] 
 
mGFR 
93.3 ml/min/1.73m2 
(82.3-105.8);36.1-150.7 
4-vMDRD 
 
77.6 ml/min/1.73m2 
(67.8-92.0);43.6-138.5 
 
4-vMDRD-e  
84.7 ml/min/1.73m2 
(71.7-102.8);43.6-167.9 
 
CG 
95.2 ml/min/1.73m2 
(83.7-110.7);51.7-162.7 
 
CKD-EPI 
95.0 ml/min/1.73m2 
(80.5-113.2);49.9-152.0 
 
Suitable for kidney 
donation 
 
Yes 
 
183/350 (52.3%) 
No 166/350 (47.4%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reason for donor 
unsuitability (n=166) 
Donor  
obesity 31/166 (18.7%) 
hypertension 26/166 (15.7%) 
low GFR(GFR<80 mL/min/1.73m2 ) and 
unexplained proteinuria/haematuria 
 
22/166 (13.3%) 
abnormality of urinary tract 21 /166 (12.7%) 
psychological / social problems 20/166 (12.0%) 
positive crossmatch / ABO 
incompatibility 
 
14/166 (8.4%) 
HIV infection 8/166 (4.8%) 
chronic hepatitis B or C infection 8/166 (4.8%) 
tuberculosis 1/166 (0.6%) 
autoimmune disease 
(thyroid/sarcoidosis) 
 
5/166 (3.0%) 
unexplained anaemia 3/166 (1.8%) 
diabetes 2/166 (1.2%) 
ischaemic heart disease/aortic 
aneurysm 
 
2/166 (1.2%) 
malignancy 1/166 (0.6%) 
liver disease 1/166 (0.6%) 
Recipient  
recipient too ill / died 10/166 (6.0%) 
transferred to another hospital                               2/166 (1.2%) 
 
Table 2: Potential living kidney donor suitability for donation at CMJAH and 
 
WDGMC (1996-2013) 
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6.2 Characteristics of living donor kidney transplant recipients 
 
There was a gradual increase in transplantation rates from 1996 to 2003, with a period 
of decline after 2004 and a subsequent surge after 2011 (Figure 1). The majority of 
transplants were carried out at CMJAH (114/183; 62.3%). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Living donor kidney transplant rates at CMJAH and WDGMC between 
 
1996 and 2013 
 
 
 
 
There were very few surgical complications observed in the recipients post-transplant 
(13/165; 7.1%), with recipient and graft survival rates at 1 year of 86.3% and 82.5% 
respectively.  For those whose grafts survived to 1 year, the median serum creatinine 
was 100 μmol/l (IQR 82-143; range 23-733 μmol/l) (Table 3). 
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Table 3. Outcomes for living donor kidney transplant recipients at CMJAH and 
 
WDGMC between 1996 and 2013 
 
  n (%)  Recipients 
 
Hospital 
CMAJH 114/183 (62.3%) 
WDGMC 69/183 (37.7%) 
 
HLA match 
0 10/183 (5.5%) 
1 23/183 (12.6%) 
2 19/183 (10.4%) 
3 54/183 (29.5%) 
4 35/183 (19.1%) 
5 4/183 (2.2%) 
6 18/183 (9.8%) 
missing 20/183 (10.9%) 
 
 
Delayed graft function 
no 146/183 (79.8%) 
yes 4/183 (2.2%) 
missing 33/183 (18.0%) 
 
 
Surgical complications 
no 133/183 (72.7%) 
yes 13/183 (7.1%) 
missing                                           37/183 (20.2%) 
 
 
 
 
 
Surgical   complications:   type 
 
(n=13) 
graft nephrectomy 6/13 (46.2%) 
ureteric 5/13 (38.5%) 
wound hematoma / haemorrhage 2/13 (15.4%) 
renal artery thrombosis/stenosis 2/13 (15.4%) 
renal vein thrombosis/stenosis 1/13 (7.7%) 
wound dehiscence/sepsis 0/13 (0.0%) 
lymphocele 0/13 (0.0%) 
other 12/13 (92.3%) 
 
Graft rejection in first 12 
months 
no 95/183 (51.9%) 
yes 14/183 (7.7%) 
missing 74/183 (40.4%) 
 
 
Diagnosis of rejection (n=14) 
clinical 8/14 (57.1%) 
biopsy proven acute rejection 6/14 (42.9%) 
missing 1/14 (7.1%) 
 
 
Recipient alive at 1year 
yes 158/183 (86.3%) 
no 2/183 (1.1%) 
missing 23/183 (12.6%) 
 
 
Graft survived at 1year 
yes 151/183 (82.5%) 
no 13/183 (7.1%) 
missing 19/183 (10.4%) 
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6.3 Performance of eGFR equations in relation to mGFR (51Cr EDTA) 
 
An assessment was done to determine the amount of data available for Bland-Altman 
comparisons prior to comparing the performance of eGFR equations in relation to 
mGFR. Of a total sample of 350 potential donors, the main method comparisons are 
limited to 154-233 cases, i.e. 44-66% of the data set (appendix C). There was an 
insufficient sample size for CCr and it was therefore excluded from the analysis. The 
median donor mGFR, for all those who screened, was 93.3 mL/min/1.73m2 (IQR 82.3- 
105.8 mL/min/1.73m2; range 36.1-150.7 mL/min/1.73m2). Details of Bland-Altman 
 
analyses for each of the eGFR equations will follow, namely the CG equation, 4v- 
MDRD (without adjustment for ethnicity); 4v-MDRD-e (with adjustment for ethnicity); 
CKD-EPI (without adjustment for ethnicity); CKD-EPI-e (with adjustment for ethnicity). 
For all Bland Altman analyses the difference (bias) was calculated as [eGFR – mGFR]. 
In all the plots that are depicted: black line = reference line for zero bias; green line = 
mean bias; blue lines: 95% limits of agreement (LOA). 
 
 
 
 
6.3.1. Comparison of mGFR to the CG equation 
 
There was no significant bias between the average GFR predicted by the CG equation 
and mGFR. The CG equation yielded an average GFR that was 2.3 mL/min/1.73m2 
higher than the mGFR. Although the average bias between the two methods was not 
significant, the bias became more negative (-0.54 mL/min/1.73m2) for every unit 
increase in mGFR. This was confirmed by a regression of the bias vs mGFR, which 
showed that the bias was significantly affected by mGFR (p<0.0001), but there was no 
significant difference in the variation of the bias with respect to mGFR.  The adjusted 
LOA are shown by the red lines in the Bland-Altman plot in figure 2. 
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Figure 2. Bland-Altman plot for CG equation vs mGFR 
(black line = reference line for zero bias; green line = mean bias; blue lines: 95% limits of agreement 
(LOA); red lines: adjusted 95% limits of agreement (LOA)) 
 
 
Regression of the CG measurements on the mGFR measurements showed poor 
correspondence. By adding further terms to the regression between the bias 
(dependent variable) and mGFR (independent variable), the effect of age, gender, 
ethnicity and weight on the bias was explored. There was no effect of ethnicity 
(p=0.079) or weight (p=0.30) but there were significant effects of the remaining 
variables on the bias which included: a negative bias of -0.80 mL/min/1.73m2 for every 
year of age (p<0.0001) and a positive bias of +7.0 mL/min/1.73m2 for females 
compared to males (p=0.042). 
 
When age and gender, as well as their interaction, were included in the regression the 
interaction term was not significant and was removed.  The main effects of age and 
gender persisted and were significant (p<0.0001, and 0.029 respectively) with a 
negative bias (-0.80 mL/min/1.73m2) for every year of age, and a positive bias (+7.0 
mL/min/1.73m2) for females compared to males. These effects are illustrated in table 
4.  
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Table 4: Regression of CG on mGFR 
 
Parameter Estimate 
Standard 
Error t Value Pr > |t| 
Intercept 88.30 12.03 7.34 <.0001 
mGFR -0.64 0.09 -7.28 <.0001 
age at screening -0.80 0.18 -4.55 <.0001 
gender female 7.03 3.18 2.21 0.029 
 
 
 
6.3.2 Comparison of mGFR to 4v-MDRD equation  
 
There was a significant negative bias between these two methods. On average, the 
 
4v-MDRD was 16 mL/min/1.73m2 lower than mGFR. However, this bias was not 
constant across all levels of mGFR, rather it became increasingly negative (-0.77 
mL/min/1.73m2) for every unit increase in mGFR. This effect was confirmed by a 
regression of the bias vs mGFR, which showed that the bias was significantly affected 
by mGFR (p<0.0001) but there was no significant difference in the variation of the 
bias with respect to mGFR. The red lines in figure 3 show the adjusted LOA. 
 
 
 
Figure 3. Bland-Altman plot for 4v-MDRD vs mGFR 
(black line = reference line for zero bias; green line = mean bias; blue lines: 95% limits of agreement 
(LOA); red lines: adjusted 95% limits of agreement (LOA)) 
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Regression of the 4v-MDRD measurements on the mGFR measurements showed 
their correspondence was poor. By adding further terms to the regression between the 
bias and mGFR, the effect of age, gender, ethnicity and weight on the bias was 
explored. There was no effect of gender (p=0.12) but there were significant effects of 
the remaining variables on the bias which included: a negative bias of -0.41 
mL/min/1.73m2 for every year of age (p=0.0014); a negative bias of -0.32 
mL/min/1.73m2 for every kilogram of weight (p=0.0006); in black donors compared to 
white, a positive bias of 6.8 mL/min/1.73m2 (p=0.013) was shown. 
 
When age, ethnicity and weight, as well as their interactions, were included in the 
regression, the interaction terms and the effect of ethnicity were not significant and 
were removed. However, the main effects of age and weight remained significant 
(p=0.037 and 0.003 respectively) with a negative bias for every year of age (-0.30 
mL/min/1.73m2) and every kilogram of weight (-0.28 mL/min/1.73m2). These effects 
are demonstrated in table 5. 
 
Table 5: Regression of 4v-MDRD on mGFR 
Parameter Estimate Standard 
Error 
t Value Pr > |t| 
Intercept 81.00 10.68 7.58 <.0001 
 mGFR -0.68 0.07 -9.26 <.0001 
age at screening -0.30 0.14 -2.10 0.037 
weight -0.28 0.09 -2.99 0.0031 
 
6.3.3. Comparison of mGFR to 4v-MDRD-e equation 
There was a significant negative bias between these two methods. The average the 4v- 
MDRD-e was 8 mL/min/1.73m2 lower than mGFR. However, this bias was not 
constant across all levels of mGFR, rather it became increasingly negative (-0.70 
mL/min/1.73m2) for every unit increase in mGFR. This effect was confirmed by a 
regression of the bias vs mGFR, which showed that the bias was significantly affected 
by mGFR (p<0.0001), but there was no significant difference in the variation of the bias 
with respect to mGFR. The adjusted LOA are shown by the red lines in the Bland-
Altman graph in figure 4.  
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Figure 4. Bland-Altman plot for 4v-MDRD-e vs mGFR 
(black line = reference line for zero bias; green line = mean bias; blue lines: 95% limits of 
agreement  (LOA); red lines: adjusted 95% limits of agreement (LOA)) 
 
Regression of the 4v-MDRD-e measurements on the mGFR measurements 
revealed poor correspondence. By adding further terms to the regression between 
the bias and mGFR, the effect of age, gender, ethnicity and weight on the bias was 
explored. There was no effect of gender (p=0.73) but there were significant effects of 
the remaining variables on the bias which included: a negative bias of -0.58 
mL/min/1.73m2 for every year of age (p=0.0009); a negative bias of -0.47 
mL/min/1.73m2 for every kilogram of weight (p=0.0001); in black patients compared  
to  white,  a  positive  bias of 24.2mL/min/1.73m2 (p<0.0001) was demonstrated. 
 
When age, ethnicity and weight, as well as their interactions, were included in the 
regression the interaction terms were not significant and were removed. However, the 
main effects of age, ethnicity and weight remained significant (p=0.026, <0.0001, and 
0.014 respectively) with a negative bias for every year of age (-0.36 mL/min/1.73m2) 
 
and kilogram of weight (-0.26 mL/min/1.73m2) and a positive bias (+21.7 
mL/min/1.73m2) for Black compared to white donors.  These effects are 
demonstrated in table 6. 
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Table 6: Regression of 4v-MDRD-e on mGFR 
 
Parameter Estimate Standard 
Error 
t Value Pr > |t| 
Intercept 73.17 12.78 5.73 <.0001 
mGFR -0.60 0.08 -7.35 <.0001 
age at screening -0.36 0.16 -2.25 0.026 
race asian 5.33 5.15 1.04 0.30 
race black 21.67 3.19 6.79 <.0001 
race coloured -6.36 4.81 -1.32 0.19 
race white 0.00 . . . 
weight -0.26 0.11 -2.49 0.014 
 
 
6.3.4. Comparison of mGFR to the CKD-EPI equation 
 
There was a significant negative bias between the two methods. On average the CKD- 
EPI method underestimated GFR by 6.4 mL/min/1.73m2. However, the bias was not 
constant across all levels of mGFR, rather it became increasingly negative (-0.74 
mL/min/1.73m2) for every unit increase in mGFR. This effect   was confirmed by a 
regression of the bias vs mGFR, which showed that the bias was significantly 
affected by mGFR (p<0.0001), but there was no significant difference in the variation 
of the bias with respect to mGFR.  The bias became more negative by an estimated 
0.74 mL/min/1.73m2 for every unit increase in mGFR.  The adjusted LOA are shown 
by the red lines in the Bland-Altman plot (figure 5).  
 
Regression of the CKD-EPI measurements on the mGFR measurements revealed 
their correspondence was poor. By adding further terms to the regression between 
the bias and mGFR, the effect of age, gender, ethnicity and weight on the bias was 
explored. There was no effect of gender (p=0.40) but there were significant effects of 
the remaining variables on the bias which included: A negative bias of -0.64 
mL/min/1.73m2 for every year of age (p<0.0001); a negative bias of -0.35 
mL/min/1.73m2 for every kilogram of weight (p=0.0001); in black donors compared to 
white, a positive bias of 7.6 mL/min/1.73m2 (p=0.0046) was demonstrated. 
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Figure 5. Bland-Altman plot for CKD-EPI equation vs mGFR 
(black line = reference line for zero bias; green line = mean bias; blue lines: 95% limits of agreement  
(LOA); red lines: adjusted 95% limits of agreement (LOA)) 
 
When age, ethnicity and weight, as well as their interactions, were included in the 
regression, the interaction terms were not significant and were removed. However, the 
main effects of age and weight remained significant (p<0.0001 and 0.0040  
respectively)  with  a  negative  bias  for  every  year  of  age  (-0.57 
mL/min/1.73m2) and kilogram of weight (-0.26 mL/min/1.73m2). Post-hoc tests showed 
no ethnicity differences. These effects are depicted in table 7. 
 
Table 7: Regression of CKD-EPI on mGFR 
 
Parameter Estimate 
Standard 
Error t Value Pr > |t| 
Intercept 92.57 10.91 8.48 <.0001 
bamean -0.62 0.07 -8.91 <.0001 
age at screening -0.57 0.14 -4.14 <.0001 
race asian 5.47 4.39 1.25 0.21 
race black 4.07 2.73 1.49 0.14 
race coloured -6.83 4.10 -1.67 0.097 
race white         
weight -0.26 0.09 -2.92 0.004 
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6.3.5. Comparison of mGFR to the CKD-EPI-e equation 
 
There was no significant bias between the average GFR values obtained by the CKD- 
EPI-e and the mGFR; although the average GFR obtained by the CKD-EPI (with 
adjustment for ethnicity) was 0.6 mL/min/1.73m2 higher than the mGFR, this was not 
significantly different to zero. However, the bias was not constant across all levels of 
mGFR, rather it became increasingly negative (-0.67 mL/min/1.73m2) for every unit 
increase in mGFR.  Thus the estimating equation progressively underestimated GFR 
with preserved kidney function. This effect was confirmed by a regression of the bias 
vs mGFR, which showed that the bias was significantly affected by mGFR (p<0.0001), 
but there was no significant difference in the variation of the bias with respect to 
mGFR.  The bias became more negative by an estimated 0.67 mL/min/1.73m2 for 
every unit increase in mGFR.  The red lines in the Bland-Altman plot (figure 6) show 
the adjusted LOA 
 
  
Figure 6. Bland-Altman plot for CKD-EPI-e vs mGFR 
 (black line = reference line for zero bias; green line = mean bias; blue lines: 95% limits of agreement              
(LOA); red lines: adjusted 95% limits of agreement (LOA)) 
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Regression of the CKD-EPI- e  measurements on the mGFR measurements 
showed that their correspondence was poor. By adding further terms to the regression 
between the bias and mGFR, the effect of age, gender, ethnicity and weight on the 
bias was explored. There was no effect of gender (p=0.98) but there were significant 
effects of the remaining variables on the bias which included: a negative bias of -0.82 
mL/min/1.73m2 for every year of age (p<0.0001); a negative bias of -0.49 
mL/min/1.73m2 for every kilogram of weight; in black donors compared to white, a 
positive bias of 21.8 mL/min/1.73m2 (p<0.0001) was observed. 
 
When age, ethnicity and weight, as well as their interactions, were included in the 
regression the interaction terms were not significant and were removed. However, the 
main effects of age, ethnicity and weight remained significant (p<0.0001, <0.0001, and 
0.0045 respectively) with a negative bias for every year of age (-0.61 mL/min/1.73m2) 
and kilogram of weight (-0.28 mL/min/1.73m2) and a positive bias (+18.2 
mL/min/1.73m2) for Black compared to White donors. These effects are 
demonstrated in table 8. 
 
Table 8: Regression of CKD-EPI-e on GFR 
 
Parameter Estimate Standard 
Error 
t Value Pr > |t| 
Intercept 92.91 11.69 7.95 <.0001 
mGFR -0.60 0.08 -7.97 <.0001 
age at screening -0.61 0.15 -4.15 <.0001 
race asian 5.38 4.70 1.14 0.25 
race black 18.20 2.93 6.21 <.0001 
race coloured -6.88 4.39 -1.57 0.12 
race white 0.00 . . . 
weight -0.28 0.10 -2.88 0.0045 
 
 
 
 
  
24 
 
6.4 Performance of eGFR equations with reference to the clinical cut-off of 
mGFR >=80 mL/min/1.73m2 
 
When assessing kidney function in donors, a clinical cut-off of mGFR >=80 
mL/min/1.73m2 defines eligibility for kidney donation, across all age groups. Based 
upon this practice, the performance of the eGFR equations that were evaluated in 
this study were further assessed. The dataset was divided into two groups: GFR <80 
mL/min/1.73m2 and >=80 mL/min/1.73m2. For each group the following parameters 
were calculated: median percentage bias (difference between eGFR and mGFR); 
95% confidence interval for the percentage bias; median bias (difference between 
eGFR and mGFR); IQR for the bias; P30 – which is the accuracy within 30% of 
measured GFR, and root mean squared error (table 9).  
 
Table 9. Performance of eGFR equations with reference to the clinical cut-off 
of mGFR >=80 mL/min/1.73m2 for eligibility for kidney donation 
 
 
 
 
 
Equation 
 
 
mGFR 
(mL/min
/ 
1.73m2) 
 
 
 
n 
 
 
Median 
percentage 
bias (%) 
 
 
95% CI for 
percentage 
bias (%) 
 
 
P30 
(%) 
 
Median 
Bias 
(mL/min/ 
1.73m2 ) 
 
 
Bias (IQR) 
(mL/min/ 
1.73m2 ) 
 
 
RMSE 
(mL/min/ 
1.73m2 ) 
 
4v-MDRD 
<80 46 1.5 -7.2 to 8.8 84.8 0.9 -8.9 to 10.1 17.1 
>=80 187 -22.3 -24.7 to -19.0 69.0 -20.9 -34.6 to -7.7 29.4 
Overall 233 -18.6 -22.2 to -15.9 72.1 -17.0 -30.8 to -4.5 27.4 
 
4v-MDRD-e 
<80 43 6.0 1.1 to 19.2 65.1 4.2 -5.6 to 25.2 21.7 
>=80 170 -13.9 -17.8 to -6.6 74.1 -14.2 -28.4 to 4.1 27.3 
Overall 213 -7.4 -14.2 to -5.0 72.3 -6.7 -24.3 to 6.0 26.3 
 
CG 
<80 31 17.1 6.8 to 37.2 64.5 13.0 4.5 to 27.1 26.2 
>=80 123 -2.2 -7.8 to 3.8 88.6 -2.1 -16.5 to 11.7 20.8 
Overall 154 3.4 -1.1 to 6.6 83.8 3.1 -13.5 to 13.5 22.0 
 
CKD-EP 
<80 46 15.8 5.6 to 26.5 73.9 9.6 -1.9 to 20.0 21.1 
>=80 187 -10.5 -13.8 to -5.9 82.4 -10.8 -25.5 to 2.0 22.9 
Overall 233 -6.4 -10.4 to -2.3 80.7 6.0 -19.2 to 7.4 22.6 
 
CKD-EPI-e 
<80 43 19.0 12.4 to 28.1 67.4 12.6 0.7 to 34.0 27.2 
>=80 170 -2.7 -8.3 to 2.3 81.8 -2.5 -19.1 to 13.3 23.5 
Overall 213 2.0 -2.8 to 7.1 78.9 1.9 -14.8 to 15.4 24.3 
 
 
 
In order to determine whether the eGFR equations could assist clinicians to 
correctly identify potential donors for donation, the PPV and NPV to determine 
donors with GFR<80 mL/min/1.73m2 was calculated for each of the estimation 
equations (table 10). 
  
25 
 
  Table 10. Statistics to identify donors with GFR < 80 mL/min/1.73m
2
 
 
 
 
Equation 
 
 
n 
 
Sensitivity (%) 
(95% CI) 
 
Specificity (%) 
(95% CI) 
 
PPV (%) 
(95% CI) 
 
NPV (%) 
(95% CI) 
MDRD 233 74 (59-86) 43 (36-51) 24 (17-32) 87 (79-93) 
MDRD-e 213 58 (42-73) 61 (53-68) 27 (18-37) 85 (78-91) 
CG 154 48 (30-67) 84 (76-90) 43 (26-61) 87 (79-92) 
CKD-EPI 233 48 (33-63) 67 (60-74) 27 (17-37) 84 (77-89) 
CKD-EPI-e 213 42 (27-58) 77 (70-83) 32 (20-45) 84 (77-89) 
   
 
7. Discussion 
 
 
This is one of the few studies from the sub Saharan African region which has evaluated 
the performance of various GFR estimation equations in relation to a gold standard 
measured GFR method. In addition, it is the first to assess the performance of these 
estimating equations in potential kidney donors with predominantly normal kidney 
function (median measured GFR 93.3 mL/min/1.73m2 (IQR 82.3-105.8 
mL/min/1.73m2; range 36.1-150.7 mL/min/1.73m2). 
 
The majority (39.7%) of potential donors in this study were young women of black 
ethnic origin (table 1). These findings are similar to those of a previous South African 
study where the mean donor age was 35.2 years, although only 24% were black (7). 
This study is therefore particularly relevant because the young kidney donor population 
has a predictably long life expectancy which may be compromised if their kidney 
function is not adequately evaluated at donation. Furthermore, the donor work up can 
be more costly due to measured GFR testing (when compared to a serum creatinine 
and estimated GFR calculation) and its use requires scientific justification. This cost 
may be compounded by the high failure rates of screened donors, as demonstrated in 
this study, which necessitates screening of several donors per recipient. Therefore, an 
accurate and affordable eGFR equation for assessing kidney function in healthy 
donors would be ideal, particularly in resource constrained environments. 
Almost half of the potential donors screened were found to be unsuitable for living 
kidney donation (47.7%) (table 2). These results concur with a previous study from 
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South Africa and with internationally published data. In a study done at CMJAH in 
Johannesburg, South Africa, it was found that 59.7% of potential living kidney donors 
either withdrew or were withdrawn due to medical and non-medical reasons (7). 
Similarly, internationally, in a study done at St. Michael’s hospital in Canada to 
determine the causes of living kidney donor rejection and deferral, 50.2% of potential 
living kidney donors were rejected due to medical reasons (5). In a Catholic university 
in Rome, Italy, a study was done to determine reasons for exclusion of potential living 
kidney donors referred to the centre and 56.9% of potential living kidney donors were 
excluded due to medical and non-medical reasons (9). 
 
With regard to the reasons for unsuitability for live kidney donation, in this study the 
main reasons were obesity, hypertension, abnormalities of the urinary tract  and 
unexplained glomerular disease, characterised by a low GFR (GFR< 80 
mL/min/1.73m2), and or unexplained haematuria/proteinuria (table 2). This is similar 
to other studies where it was found that the main reasons for non-donation were renal 
in origin (including non-orthostatic proteinuria, abnormal GFR and urological 
problems), obesity, hypertension and diabetes (5, 7, 9). This finding suggests that 
there is a high burden of undiagnosed CKD in this community. Of those who were 
found to be eligible, all underwent living kidney donation. With regard to the 
outcomes of these procedures, there were very few surgical complications in the 
recipients, and no complications were documented in the donors. Recipient  and 
graft survival at one  year  post transplant  was 86.3% and  82.5% respectively, 
which is comparable to other published studies from South Africa (33), but below the 
internationally achieved rates for living donors (34, 35). 
 
The estimating equations for predicting kidney function that were assessed in this 
study performed poorly when compared to the gold standard radionuclear measured 
GFR. In this sample, the 4-v MDRD (with and without ethnicity adjustment) and the 
CKD-EPI (without ethnicity adjustment) equations significantly underestimated the 
average measured GFR (negative bias of -8 mL/min/1.73m2, -16 mL/min/-1.73m2 and 
-6.4  mL/min/1.73m2   respectively).  On the  contrary,  the  bias associated  with  the 
 
average measured  GFR using the  CG and  CKD-EPI  (with  ethnicity adjustment) 
 
equations was not significant (2.3 mL/min/1.73m2 and 0.6 respectively). 
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The negative bias observed with each of the estimating equations was not 
proportionately distributed across all levels of measured GFR. In fact, the bias became 
more negative i.e. measured GFR was increasingly underestimated over the range of 
50 -150mL/min/1.73m2, irrespective of adjustments for ethnicity. This has 
important implications for the use of estimating equations to evaluate kidney function 
in healthy donors, where the expected GFR is high. 
 
Currently in South Africa, the 4v-MDRD and the CKD-EPI equations are used by 
various clinical laboratories for reporting eGFR. Historically, the 4v-MDRD equation 
was developed in those with CKD and its poor performance in healthy donors could 
perhaps be explained. On the other hand, the CKD-EPI equation was developed to 
improve accuracy in those with better kidney function (>60 mL/min/1.73m2) which 
makes its poor performance in this study more questionable. 
 
It was interesting that the CG equation had the lowest bias for predicting the average 
measured GFR in this study, although this equation is no longer routinely used by 
laboratories. There are no comparable studies from sub Saharan Africa, but other 
published studies from Amsterdam, Korea and Pakistan found the CKD-EPI equation 
to have the least bias and best performance in predicting GFR; the average measured 
GFR in these studies ranged from 72.6mL/min/1.73m2 to 120mL/min/1.73m2 (36-38). 
However, in a study done at Cleveland clinic, U.S.A that evaluated the performance of 
creatinine based measures of GFR in a cohort of living kidney donors, the CG had 
less bias than the 4v-MDRD equation in predicting GFR (-0.5mL/min/1.73m2 and -
11.0mL/min/1.73m2 respectively), with a mean measured GFR of 106mL/min/1.73m2 
(39), this is similar to the findings of this study. 
 
 
In order to explain the negative bias that was observed when predicting measured 
GFR, the impact of gender, age, weight and ethnicity was explored for each estimating 
equation. With respect to age, it was found that all GFR estimation equations showed 
a negative bias with increasing age. The implication for the older living donor is that if 
eGFR is used as the only measure of kidney function, they may not be accepted for 
donation even though their GFR may be appropriate. The question is whether it is fair 
to use a single cut off GFR for living kidney donation of all ages. 
 
Some studies have proposed a correction factor for age which would be consistent 
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with the findings of our study, although we have not investigated the relationship 
between mGFR and increasing age. The British transplant society guidelines 
recommend a rigorous work up of older donors to ensure their suitability. The age- 
related decline in GFR has been accommodated by recommending GFR evaluation 
using a gold standard method and adjusting for age as per table 11.  
 
Table 11. Acceptable GFR by donor age before donation 
 
 
Donor age(yr) Acceptable GFR before donation, corrected 
for BSA, (mL/min/1.732) 
Up to 46 80 
47-50 77 
51-60 68 
61-70 59 
71-80 50 
 
 
 
With respect to weight, the CG estimates were not affected by donor weight (as it 
adjusts for this in the formula). However, both 4v-MDRD and the CKD-EPI equations 
underestimated GFR with increasing donor weight. The implication for living kidney 
donation is that potential donors with a higher BMI are more likely to be rejected even 
though their mGFR may be within acceptable limits. This suggests the need for a 
weight correction factor in this population. 
 
There was no effect of gender on the 4v-MDRD and CKD-EPI estimates in our study. 
However, the CG estimates showed a positive bias of 7 mL/min/1.73m2 for female 
compared to male donors, thus the CG equation overestimated GFR in female 
compared to male donors. The reason for this is unclear, however, it may suggest that 
the gender factor used in the CG equation is not be optimal. 
 
In Black compared to white South Africans, use of the ethnicity factor resulted in a 
significant overestimation of mGFR for the 4v-MDRD equation (by 24.2 
mL/min/1.73m2 compared to 6.8 mL/min/1.73m2 without it). Similarly, the ethnicity 
factor significantly overestimated mGFR for the CKD-EPI equation (by 21.8 
mL/min/1.73m2, compared to 7.6 mL/min/1.73m2, without the ethnicity factor). The 
implication for living kidney donation is that potential donors with sub-optimal kidney 
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function may be accepted for donation if screened using the 4v-MDRD and the CKD-
EPI equations with ethnicity correction. In South Africa today, the laboratories use the 
CKD-EPI equation without adjustment for ethnicity, which is consistent with the 
findings of this study. 
 
When comparing the performance of the eGFR equations in relation to mGFR and the 
clinical cut-off of 80 mL/min/1.73m2, in this study, the 4v-MDRD equation (without 
adjustment for ethnicity) had the highest sensitivity for determining donors with GFR 
<80 mL/min/1.73m2, while the CG equation had the highest specificity. Similar 
findings were reported in a U.K study which also demonstrated the 4v-MDRD to have 
a relatively higher sensitivity for identifying potential donors with GFR<80 
mL/min/1.73m2 compared to the CG and CKD-EPI equations (40). However, as in 
various other international studies, the sensitivity, specificity and positive predictive 
value of all four prediction equations for determining donors with GFR <80 
mL/min/1.73m2 was poor (38-41).  In  one  study from  India  assessing  the  
performance  of  GFR  estimation equations in evaluating potential living kidney 
donors, none of the GFR estimation equations was found to have sufficient sensitivity 
or specificity to reliably predict donors with GFR=>80 mL/kg/1.73m2  (42). Based on 
our findings therefore, we would not recommend the use of these equations as a 
sufficient method for screening potential kidney donors in South Africa. 
 
 
8. Limitations of the study 
 
Due to the retrospective nature of this study there were missing results that precluded 
a complete data set. While this remains a limitation, the levels of missing data have 
been included in all the results in this study to ensure completeness. The inability to 
evaluate the performance of the 24 hour urine creatinine clearance as a method of 
estimating GFR is another limitation. This was in part due missing data, but also due 
to the lack of uniformity in the work up testing of patients – as practice does vary 
between sites and not all potential donors perform this test. Inferences from this study 
may be limited as it was confined to one geographical region of the country. On this 
basis, the findings of this study may be used to inform future studies that would 
preferably be prospective and multi-centre in design. 
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9. Recommendations 
 
 
Based on the findings of this study, the following recommendations may be helpful to 
inform policy on the process of living kidney donor evaluation in South Africa: 
 
1. A gold standard measured GFR test is the preferred test for the evaluation of kidney 
function in all potential living kidney donors 
2. Rather than a single cut-off value of 80 mL/min/1.73m2, a correction factor for age 
should be considered when assessing GFR in potential living kidney donors, 
particularly in the older age group. The development of this correction factor could be 
informed by the data from this study. 
 
3. In the preliminary screening of potential living kidney donors using estimating 
equations for GFR, the ethnicity correction factor should not be used in estimating GFR 
using the v-MDRD and the CKD-EPI equations 
 
4. Further studies to determine need for a weight correction factor for the 4-vMDRD 
and the CKD-EPI equations as well as determining if the gender factor for the CG 
equation is optimal. 
 
 
 
 
10. Conclusion 
 
Most potential donors were young, female and of black ethnic origin, and almost half 
of the potential living donors who were evaluated were ineligible to donate. The most 
common reasons for ineligibility were obesity, hypertension, abnormalities of the 
urinary tract and low measured GFR. When comparing the performance of the eGFR 
equations to measured GFR, they all performed poorly, particularly at higher measured 
GFR. Based on the findings of this study, it is appropriate that measured GFR should 
be the gold standard for evaluating kidney function in potential living kidney donors in 
South Africa. This is in line with the British Transplant society guidelines  which 
recommend that GFR in potential living kidney donors should be measured using a 
reference GFR procedure, for example, 51Cr EDTA (43). 
 
 
  
31 
 
 
Appendix A 
 
 
Ethical clearance certificate 
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Appendix B 
 
 
 
 
PROTOCOL FOR CR51-EDTA GFR 
 
1. Work out the different quantities of Cr 51-EDTA and saline – for e.g., 0.4mL 
Cr51- EDTA AND 5.6mL Saline – make enough for the amount of patients to be 
done, plus 1mL for the standard – mix in a vial. 
 
 
 
2. Withdraw 1mL of the solution into a 1mL syringe, take the needle off and then 
weigh the syringe three times and record weights. 
 
 
3. Dispense the contents of the standard in a 100mL flask. 
 
 
 
4. Measure the empty syringe without the needle, three times, and record weights. 
 
 
 
5. Add distilled water to the flask, till 100 mL, until the lower level of the meniscus. 
 
 
 
6. Put parafilm over the top, and mix. 
 
 
 
7. Take a 1 mL pipette and dispense 1mL in each of 3 labelled standard tubes – 
put date on. 
 
 
8. Count standard tubes each for 10 mins. If the counts are around 5000 cpm, then 
the dose per patient is 5 mL. If the counts are higher, 6000 cpm, then give the 
patient 4 mL If the counts are lower, 4000 cpm, then give the patient 6mL. 
 
 
 
9. Draw up the dose of the patient, weigh syringe without needle, three times and 
record weights. 
 
 
10. Before you inject the patient, he/she must have a glass of water to drink, and 
they must continue to drink one glass of water every half hour during the entire test. 
The patient may empty their bladders when necessary. During the test they can eat, 
but NO PROTEIN or CAFFEINE. 
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11. Inject patient, record time, and in which arm the injection was given. Also record 
the weight and height of the patient – these measurements are necessary for 
analysis of the GFR. 
 
 
12. Weigh empty syringe, without needle, three times and record weights. 
 
 
 
13. Draw blood samples, from opposite arm to injection, at 3 hours post injection, into 
green-topped heparinised tubes. Draw three tubes. Record exact time when sample 
was drawn – important that the blood is drawn at exactly 3 hours post injection. 
 
 
14. Spin each tube of blood in a centrifuge for 10mins. 
 
 
 
15. Withdraw 1 mL of supernatant with a 1 mL pipette carefully, and put into a 
tube, labelled with the correct time of sample. 
 
 
16. Try to withdraw 3 mLs of the supernatant into 3 different tubes. 
 
 
 
17. Put the three standard tubes, the three 3hr samples into a rack, and count each 
tube for 10 mins, using protocol 2 clip. 
 
 
18. Once counting has been completed, enter figures into excel spreadsheet to 
determine GFR – enter weights of dose and standard, enter weight and height of 
patient, enter name, age, sex, enter counts of standard and the two samples. 
 
 
19. Print GFR result out and a report and fax or deliver to relevant doctor. 
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Appendix C 
 
 
 
Potential donors who had m GFR data as well as data for each of the 
comparative eGFR measures 
 
GFR measure Number of cases 
RN 286 
MDRD-b 297 
MDRD-e 274 
CG 209 
CKD-EPI-b 297 
CKD-EPI-e 280 
Main comparisons Number of cases 
RN vs. MDRD-b 233 
RN vs. MDRD-e 213 
RN vs. CG 154 
RN vs. CKD-EPI-b 233 
RN vs. CKD-EPI-e 213 
Exploration of main comparisons Number of cases 
RN vs. MDRD-b 233 
RN vs. MDRD-b with age 233 
RN vs. MDRD-b with gender 233 
RN vs. MDRD-b with ethnicity 213 
RN vs. MDRD-b with weight 189 
RN vs. MDRD-e 213 
RN vs. MDRD-e with age 213 
RN vs. MDRD-e with gender 213 
RN vs. MDRD-e with ethnicity 213 
RN vs. MDRD-e with weight 175 
RN vs. CG 154 
RN vs. CG with age 154 
RN vs. CG with gender 154 
RN vs. CG with ethnicity 144 
RN vs. CG with weight 154 
RN vs. CKD-EPI-b 233 
RN vs. CKD-EPI-b with age 233 
RN vs. CKD-EPI-b with gender 233 
RN vs. CKD-EPI-b with ethnicity 213 
RN vs. CKD-EPI-b with weight 189 
RN vs. CKD-EPI-e 213 
RN vs. CKD-EPI-e with age 213 
RN vs. CKD-EPI-e with gender 213 
RN vs. CKD-EPI-e with ethnicity 213 
RN vs. CKD-EPI-e with weight 175 
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